Quarterly report pursuant to Section 13 or 15(d)

Business and Organization (Details)

v3.5.0.2
Business and Organization (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended
Aug. 31, 2016
USD ($)
$ / shares
shares
Aug. 31, 2015
USD ($)
$ / shares
shares
May 31, 2015
USD ($)
$ / shares
shares
Sep. 30, 2016
employee
Business Acquisition [Line Items]        
Number of sales employees | employee       420
Transition Therapeutics        
Business Acquisition [Line Items]        
Consideration transferred $ 58,500      
Bio-Reference        
Business Acquisition [Line Items]        
Consideration transferred   $ 950,148    
Value of replacement stock options awards to holders of Bio-Reference stock options   $ 2,259    
EirGen        
Business Acquisition [Line Items]        
Consideration transferred     $ 133,800  
Value of replacement stock options awards to holders of Bio-Reference stock options     33,600  
Total purchase price     $ 100,200  
Common Stock        
Business Acquisition [Line Items]        
Stock price per share (in dollars per share) | $ / shares $ 9.10 $ 12.38 $ 13.88  
Common Stock | Transition Therapeutics        
Business Acquisition [Line Items]        
Common stock received | shares 6,431,899      
Common Stock | Bio-Reference        
Business Acquisition [Line Items]        
Common stock received | shares   76,566,147    
Acquired entity share price (in dollars per share) | $ / shares   $ 34.05    
Common Stock | EirGen        
Business Acquisition [Line Items]        
Common stock received | shares     2,420,487